EP 55: 5 Interventional trials that will change your practice: Review of ESC 21 Dr Mirvat Alasnag
In the second ESC 2021 episode of Parallax, Dr Ankur Kalra\u2019s guest is Dr. Mirvat Alasnag, interventional Cardiologist and Director of Catheterization Laboratory at the King Fahad Armed Forces Hospital (KFAFH) in Saudi Arabia. Dr Alasnag was a programme committee member at this year\u2019s ESC and regional PI of one of the late-breaking trials presented.\n\nAnkur invites Mirvat to review the interventional cardiology highlights of the congress. Mirvat summarises the background and latest evidence from the trials and their importance. Ankur and Mirvat discuss the strategies they apply currently and how they think the novel data will guide their decision-making.\n\nTrials covered in detail include:\nSTOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome\nTOMAHAWK: immediate angiography after out-of-hospital cardiac arrest\nENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation\nRIPCORD 2: does routine pressure wire assessment influence management strategy of coronary angiography for diagnosis of chest pain?\nMASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients\n\nQuestions and comments can be sent to \u201cpodcast@radcliffe-group.com\u201d and may be answered by Ankur in the next episode. Guest @mirvatalasnag hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.\nBrought to you by Edwards: www.edwardstavr.com